Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

For Bristol, Onglyza Disappoints And Health Care Reform Takes A Toll

Executive Summary

The new health care reform statute will have a significant impact on Bristol-Myers Squibb's sales in 2010 and 2011, the company said during a first quarter sales and earnings call April 29 in which the drug maker announced it is revising earnings guidance for the year as a result

You may also be interested in...



Nothing To SAVOR For Bristol/AZ From Onglyza Results

Bristol and AstraZeneca announced mixed results from a post-marketing study for their diabetes drug Onglyza that will likely have no commercial ramifications for the drug, which has been a disappointment since its launch in 2009.

Nothing To SAVOR For Bristol/AZ From Phase IV Results

Bristol and AstraZeneca announced mixed results from a post-marketing study for their diabetes drug Onglyza that will likely have no commercial ramifications for the drug, which has been a disappointment since its launch in 2009.

Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug

As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel